Skip to content

19-379 - Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

Status: open

A Phase II Study of Combining Talimogene Laherparepvec (T-VEC) (NSC-785349) and MK-3475 (pembrolizumab) (NSC-776864) in Patients with Advanced Melanoma Who Have Progressed on Anti-PD1/L1 Based Therapy

Treatment for Melanoma

Contact Us Or call (251) 445-9834


This phase II trial studies how well talimogene laherparepvec and pembrolizumab work in treating patients with stage III-IV melanoma.


This trial is sponsored by National Cancer Institute (NCI).

Providers Associated With This Trial

Principle Investigator

Sub Investigators

This link will open in a new tab or window.